Abstracts tagged "quality of life"

Abstract Number: 2384 • ACR Convergence 2025
Patient-Reported Quality of Life in SLE: Association with Biomarker-Derived Disease Activity Index (L-DAI) and hSLEDAI in a Prospective Cohort
Bernard Rubin¹, Rou Sore¹, Melissa Munroe¹, Daniele DeFreese¹, Adrian Holloway¹, Mohan Purushothaman¹, Yangfen Li², Hu Zeng², Uma Thanarajasingam², Judith James³ and Eldon Jupe¹, ¹Progentec Diagnostics, Inc., Oklahoma City, OK, ²Mayo Clinic, Rochester, MN, ³Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systematic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by unpredictable disease activity. The Lupus Disease Activity Index (L-DAI) is a blood-based assessment…
Abstract Number: 1551 • ACR Convergence 2025
Disease Burden and Treatment Preferences for Systemic Lupus Erythematosus: Results from a Global Real-World Survey
Zahi Touma¹, Christopher Saffore², Karim Masri³, Jerry Clewell³, Emily Goddard⁴, Grace O'Neill⁴, Madelane Foxall⁴ and Karen H. Costenbader⁵, ¹University of Toronto, Toronto, ON, Canada, ²AbbVie Inc., waukegan, IL, ³AbbVie Inc., North Chicago, IL, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: As new treatment options for systemic lupus erythematosus (SLE) become available, understanding patient burden and preferences is key to optimizing shared decision-making. This study…
Abstract Number: 1259 • ACR Convergence 2025
Patient and Caregiver Perspectives on the Burden of Disease in Uncontrolled Gout: A Cross-Sectional Survey Study
Angelo Gaffo¹, Bhavisha Desai², Abiola Oladapo³, Nana Kragh⁴, Rebekah Zincavage⁵, Brad Padilla⁵ and Naomi Schlesinger⁶, ¹Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ²Sobi, Glastonbury, CT, ³Sobi INC, Waltham, MA, ⁴Sobi, Kongens Lyngby, Denmark, ⁵Stratevi, Boston, ⁶Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT
Background/Purpose: Many patients with uncontrolled gout (UG) experience symptoms despite being on urate-lowering therapy (ULT), often requiring support from informal caregivers. UG impacts patients and…
Abstract Number: 0794 • ACR Convergence 2025
Using Artificial Intelligence to Analyze Multilingual Qualitative Data in Lupus Pregnancy Research: A Proof of Concept with Large Language Models
Romina Boers¹, Grace Terry² and Bella Mehta³, ¹Weil Cornell Medicine, New York, ²Weil Cornell Medicine, Ne wYork, ³Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ
Background/Purpose: Women with systemic lupus erythematosus (SLE), particularly those of childbearing age, face heightened risks during pregnancy, including disease flares, adverse maternal-fetal outcomes, and emotional…
Abstract Number: 2341 • ACR Convergence 2025
Bimekizumab Treatment Resulted in Long-Term Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire in Patients with Active Psoriatic Arthritis: Up to 3-Year Results from Two Phase 3 Studies
Ana-Maria Orbai¹, Dafna D. Gladman², Laura Coates³, Maarten de Wit⁴, Barbara Ink⁵, Rajan Bajracharya⁵, Patrick Healy⁶, Jérémy Lambert⁷ and Laure Gossec⁸, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁴Patient Research Partner, Stichting Tools, Amsterdam, Netherlands, ⁵UCB, Slough, England, United Kingdom, ⁶UCB, Morrisville, NC, ⁷UCB, Colombes, France, ⁸Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. The PsA Impact of Disease-12 (PsAID-12) questionnaire is…
Abstract Number: 1503 • ACR Convergence 2025
Lupus Disease Activity Adversely Affects the Quality of Life but not Intimate Relationship and Sexual Function in Indian Female Lupus Patients
Ranjan Gupta, Nilanchali Singh, Nisha Jawaliya, Rudra Prosad Goswami, Soniya Dhiman and Parul baisoya, All India Institute of Medical Sciences, New Delhi, Delhi, India
Background/Purpose: Systemic Lupus Erythematosus (SLE) disease activity can affect the normal functioning of the patients. This functioning in various domains can be assessed using quality…
Abstract Number: 1254 • ACR Convergence 2025
Symptom Burden and Treatment Experience in Fibromyalgia: Results From a National Patient Survey
Lesley Arnold¹, Zhao Yang², Parul Houston², Todd Grinnell² and Daniel Clauw³, ¹University of Cincinnati College of Medicine, Cincinnati, OH, ²Axsome Therapeutics, Inc, New York, NY, ³Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI
Background/Purpose: Fibromyalgia (FM) is a chronic, widespread pain disorder driven by dysregulated central pain processing which substantially impairs daily function and quality of life. Approved…
Abstract Number: 0789 • ACR Convergence 2025
Short Form 36 (SF-36) Health Survey Questionnaire in Health-Related Quality of Life Assessment in Patients with Inflammatory Myopathies
Almurtada Razok¹, Jasmin Taylor², Ethan Ritz³, Kristin Wipfler⁴, Kaleb Michaud⁵ and Didem Saygin⁶, ¹John H Stroger Jr Hospital of Cook County, Chicago, IL, ²Rush Medical College, Chicago, IL, ³Rush Research Informatics Core, Rush University Medical Center, Chicago, IL, ⁴FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶Rush University Medical Center, Chicago, IL
Background/Purpose: Patients with idiopathic inflammatory myopathies (IIM) experience significant impairment in their health-related quality of life (QoL); however, there are currently no validated measures to…
Abstract Number: 2337 • ACR Convergence 2025
A Mediation Analysis of Tofacitinib’s Effects on SF-36: The Roles of Fatigue, Pain, Stiffness, and Mobility in Ankylosing Spondylitis
Xenofon Baraliakos¹, Andrew G. Bushmakin², Joseph C. Cappelleri², Eleni Nikitopoulou³, You-Li Ling⁴, Mostafa Zayed⁵ and Jonathan Dominick Cicci⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²Pfizer Inc., Groton, CT, ³Pfizer Hellas, Athens, Greece, ⁴Pfizer Inc, New York, NY, USA, New York, NY, ⁵Pfizer Gulf FZ LLC, Dubai, United Arab Emirates, ⁶Pfizer Inc., New York, NY
Background/Purpose: Mediation modeling is used to determine mechanisms underlying the relationship between independent and dependent variables via other explanatory variables (“mediators”). Fatigue, pain, and morning…
Abstract Number: 1487 • ACR Convergence 2025
Whole Health Empowerment for Endotypes of Lupus (WHEEL) Program: User Testing Findings on Feasibility, Acceptability, and Opportunities for Intervention Refinement
Jennifer Rogers¹, Amanda Eudy², Connor Drake³, Tamara Somers⁴, David Pisetsky⁵, Christie Clipper⁶, Ralph Snyderman⁷, Anna Batsakes⁶, Leigh Saner⁶, Dana Burshell³, Mithu Maheswaranathan⁴, Lisa Criscione-Schreiber⁴, Rebecca Sadun⁸, Nathaniel Harris⁵, Kai Sun⁸, Kelsey Dunn⁶, Jenny Herndon⁶, Vonne Jacobs⁶ and Megan Clowse⁹, ¹Duke, Durham, NC, ²Duke University, Raleigh, NC, ³Duke University School of Medicine, Durham, ⁴Duke University School of Medicine, Durham, NC, ⁵Duke University Medical Center, Durham, NC, ⁶Duke University, Durham, ⁷Duke Center for Personalized Health Care, Durham, NC, ⁸Duke University, Durham, NC, ⁹Duke University, Chapel Hill, NC
Background/Purpose: To improve quality of life (QoL) in individuals with SLE, we developed the Whole Health Empowerment for Endotypes of Lupus (WHEEL) program—a 4-month, biweekly,…
Abstract Number: 1253 • ACR Convergence 2025
Patient Reported Outcome Measures: Assessing Resident Physician Acceptance of the Routine Assessment of Patient Index Data 3 Survey and its Impact on Physician-Patient Relationship
Nisha Sapkota¹, Chana Birnbaum², Henna Levitansky², Yevheniia Andriushchenko², Saadia Malik², Melissa Andrade², Sarang Choi² and Sima Terebelo², ¹Interfaith Medical Center, One Broolyn Health, Brooklyn, NY, ²Brookdale Hospital Medical Center, One Brooklyn Health, Brooklyn
Background/Purpose: When treating patients with rheumatological conditions, building a strong physician-patient relationship plays an important role in determining disease outcomes. The Routine Assessment of Patient…
Abstract Number: 0767 • ACR Convergence 2025
Quality of Life in Patients with Rheumatoid Arthritis with Foot and Ankle Involvement
Egla Samantha Sanchez-Peralta¹, Andrea Cantero-Castro², Karina Deciderio-Pavon³, Jesús Gilberto Espinoza-Gámez³, Irasema Arcibar-Liceaga³, Carolina De Leon-Carrillo³, Angel Kevin Garza-Elizondo¹, Ryan Jared Sanchez-De la Cruz³, Jesus Alberto Cardenas-de la Garza⁴, Dionicio A. Galarza-Delgado⁵, Diana E. Flores-Alvarado¹ and Jorge Alberto Elizondo-Rodriguez², ¹Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Nuevo Leon, Mexico, ²Traumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo Leon, Mexico, ⁴Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁵Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Foot and ankle involvement in patients with rheumatoid arthritis is a common yet often underexplored and underrecognized manifestation. This can negatively affect patients' quality…
Abstract Number: 2326 • ACR Convergence 2025
Impact of Regular Exercise, Mobility Impairment, and Obesity on Quality of Life in Patients with Axial Spondyloarthritis: A Cross-Sectional Analysis from the Brazilian Registry of Spondyloarthritis
Rafael Bassara Macedo¹, Maria Eduarda Veiga², Gustavo Resende³, Marcelo Pinheiro⁴, Claudia Marques⁵, Adriana Marinho⁶, Andressa Soares⁷, Cleandro Pires⁸, Débora Rodrigues⁹, Eduarda Souza¹⁰, Glaucio Castro¹¹, Guilherme Bulbol¹², Jamile Carneiro¹³, José Mauro Fernandes¹⁴, Manuella Ochtrop¹⁵, Maria Bernadete Gavi¹⁶, Michel Yazbek¹⁷, Nara Cavalcanti¹⁸, Natalia Machado¹⁹, Olivio Malheiro²⁰, Rejane Vieira²¹, Ricardo Lage²⁰, Rita Menin²², Rywka Golebiovski²³, Sandra Ribeiro¹², Thauana Oliveira²³, Valquiria Diniz¹⁶, Percival Sampaio-Barros²⁴ and Carla Saad², ¹Rheumatology Division, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (USP), Sao Paulo, Sao Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ³Hospital das Clinicas UFMG, Belo Horizonte, Brazil, ⁴UNIFESP/ EPM, São Paulo, São Paulo, Brazil, ⁵Hospital das Clinicas - Universidade Federal de Pernambuco - UFPE, Recife, Pernambuco, Brazil, ⁶Fundação Hospital do Acre - AC, Rio Branco, Brazil, ⁷Hospital Universitário da Universidade Federal de Santa Catarina (UFSC) - SC, Florianópolis, Brazil, ⁸UNB, Brasilia, Distrito Federal, Brazil, ⁹Fundação Hospital do Acre - AC, Rio Branco, Acre, Brazil, ¹⁰Faculdade de Medicina da Universidade Federal do Amazonas (UFAM) - AM, Manaus, Brazil, ¹¹Hospital Governador Celso Ramos (HCR) - SC, Florianópolis, Santa Catarina, Brazil, ¹²Faculdade de Medicina da Universidade Federal do Amazonas (UFAM) - AM, Manaus, Amazonas, Brazil, ¹³Hospital de Base do Distrito Federal (HBDF) - DF, Brasilia, Distrito Federal, Brazil, ¹⁴Universidade Federal do Maranhão (UFMA) - MA, São Luiz, Maranhao, Brazil, ¹⁵Hospital Universitário Pedro Ernesto / UERJ - RJ, Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁶Universidade Federal do Espírito Santo (UFES) - ES, Vitória, Espirito Santo, Brazil, ¹⁷Universidade Estadual de Campinas (UNICAMP) - SP, Campinhas, Sao Paulo, Brazil, ¹⁸Hospital das Clínicas da Universidade Federal de Pernambuco (UFPE) - PE, Recife, Pernambuco, Brazil, ¹⁹Universidade Fedral do Paraná (UFPR) - PR, Curitiba, Parana, Brazil, ²⁰Hospital das Clínicas da Universidade Federal de Minas Gerais (UFMG) - MG, Belo Horizonte, Minas Gerais, Brazil, ²¹Universidade Estadual do Ceará (UECE) - CE, Fortaleza, Ceara, Brazil, ²²Faculdade de Medicina de São José do Rio Preto (FAMERP) - SP, São José do Rio Preto, Sao Paulo, Brazil, ²³Escola Paulista de Medicina (EPM) - Universidade Federal de São Paulo (UNIFESP) - SP, São Paulo, Sao Paulo, Brazil, ²⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil
Background/Purpose: Axial Spondyloarthritis (axSpA) is a chronic inflammatory disease that impairs quality of life. While pharmacological treatment is central to axSpA management, non-pharmacological strategies are…
Abstract Number: 1461 • ACR Convergence 2025
Digital Behavioral Therapy Improves Outcome in Patients With Axial Spondyloarthritis And Persistent Pain: Results From a Randomized Controlled Trial
David Kiefer¹, Yade Sonkaya², Dietmar Krause³, Markus Voglau⁴, Bernhard Mintrop⁵, Imke Redeker⁶, Xenofon Baraliakos⁷ and Uta Kiltz⁷, ¹Ruhr-Universität Bochum; Private practice of rheumatology, Hattingen, Germany, Herne, Germany, ²Ruhr-Universität Bochum, Herne, Germany, ³Elisabeth-Gruppe, Herne, Germany, Essen, Germany, ⁴myself, Oldenburg, Germany, ⁵Private rheumatology practice, Hattingen, Germany, ⁶Ruhr University Bochum, Bochum, Germany, ⁷Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is often associated with persistent pain despite effective anti-inflammatory treatment, substantially impacting patients' quality of life. Digital health applications (DiGAs) provide…
Abstract Number: 1248 • ACR Convergence 2025
Patient and Clinician Perception and Use of Complementary and Alternative (CAM) Medicine for Rheumatic Disease
Ailia Ali¹, Sarah Sun¹, Faryal Shaikh¹, Tamiko Katsumoto², Neha Shah³, Kimberly Trotter¹ and Pankti Reid⁴, ¹University of Chicago, Chicago, IL, ²Division of Immunology and Rheumatology, Stanford University, Millbrae, CA, ³Stanford University, Palo Alto, CA, ⁴University of Chicago Medical Center, Chicago, IL
Background/Purpose: Complementary and alternative medicine (CAM) use is increasingly prevalent among patients with rheumatic diseases, yet alignment between patient practices and clinician perspectives remains poorly…

1
2
3
…
30
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].